Science Explorer Back to mapMap
Discussion
Institution · Copernicus Memorial Hospital

Most cited papers from Copernicus Memorial Hospital

Copernicus Memorial Hospital

What are the most cited papers from Copernicus Memorial Hospital?

The most cited paper from Copernicus Memorial Hospital is "Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia" (John C. Byrd et al., 2014), with 1,649 citations. Next come "Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia" (1,604) and "Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia" (934).

Showing 50 of 59 papers. Every paper with more than 93 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd et al. · New England Journal of Medicine Open access 31 May 2014 1,649
2 Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Jan A. Burger et al. · New England Journal of Medicine Open access 6 Dec 2015 1,604
3 Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia John Francis Seymour, Thomas J. Kipps, Barbara F. Eichhorst et al. · New England Journal of Medicine Open access 21 Mar 2018 934
4 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party Michael Heuser et al. · Blood Open access Nov 2021 772
5 Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer J.-Y. Douillard et al. · Annals of Oncology Open access 9 Apr 2014 615
6 Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Hagop M. Kantarjian, Neil P. Shah, Jörge E. Cortes et al. · Blood Open access 9 Dec 2011 614
7 Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Barbara F. Eichhorst, Tadeusz Robak, Emili Montserrat et al. · Annals of Oncology Open access 27 Aug 2015 613
8 Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature) Beata Smolarz, Anna Zasowska‐Nowak, Hanna Romanowicz · Cancers Open access 23 May 2022 584
9 Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study Jan A. Burger, Paul M. Barr, Tadeusz Robak et al. · Leukemia Open access 18 Oct 2019 470
10 Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial Michael Wang et al. · The Lancet Open access 11 Dec 2017 460
11 Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma Tadeusz Robak, Huiqiang Huang, Jie Jin et al. · New England Journal of Medicine Open access 4 Mar 2015 390
12 Alcohol Consumption Reported during the COVID-19 Pandemic: The Initial Stage Jan Chodkiewicz, Monika Ewa Talarowska, Joanna Miniszewska et al. · International Journal of Environmental Research and Public Health Open access 29 Jun 2020 349
13 Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial Sebastian Grosicki et al. · The Lancet Open access Nov 2020 339
14 Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study Bogumiła Ciseł et al. · Annals of Oncology Open access 6 Jun 2019 324
15 Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study Do‐Youn Oh et al. · ˜The œLancet. Gastroenterology & hepatology Open access 29 May 2024 297
16 Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Michael Heuser, Yishai Ofran, Nicolas Boissel et al. · Annals of Oncology Open access 17 Mar 2020 290
17 Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia Paul M. Barr, Carolyn Owen, Tadeusz Robak et al. · Blood Advances Open access 4 Apr 2022 283
18 The incidence and clinical analysis of non-melanoma skin cancer Magdalena A. Ciążyńska et al. · Scientific Reports Open access 22 Feb 2021 272
19 Polyphenols and Their Impact on the Prevention of Neurodegenerative Diseases and Development Izabela Grabska-Kobyłecka, Piotr Szpakowski, Aleksandra Król et al. · Nutrients Open access 4 Aug 2023 253
20 Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia Robert J. Kreitman et al. · Leukemia Open access 20 Jul 2018 253
21 Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial Andrew David Zelenetz et al. · The Lancet Oncology Open access 27 Jan 2017 250
22 Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities Arnon Philip Kater et al. · NEJM Evidence 13 May 2022 240
23 Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study Arnon Philip Kater et al. · Journal of Clinical Oncology Open access 28 Sep 2020 224
24 Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis Irmina Olejniczak‐Staruch, Magdalena A. Ciążyńska, Dorota Sobolewska-Sztychny et al. · International Journal of Molecular Sciences Open access 13 Apr 2021 214
25 Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial Jeffrey Alan Jones, Tadeusz Robak, Jennifer R. Brown et al. · The Lancet Haematology Mar 2017 202
26 Alterations in Pericyte Subpopulations Are Associated with Elevated Blood–Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer L. Tiffany Lyle, Paul R. Lockman, Chris E. Adkins et al. · Clinical Cancer Research Open access 31 May 2016 176
27 Physicochemical Investigations of Chitosan-Based Hydrogels Containing Aloe Vera Designed for Biomedical Use Anna Drabczyk, Sonia Kudłacik‐Kramarczyk, Magdalena Głąb et al. · Materials Open access 9 Jul 2020 169
28 Skin lesions in chronic lymphocytic leukemia Ewa Robak, Tadeusz Robak · Leukemia & lymphoma/Leukemia and lymphoma 2007 165
29 Serum levels of interleukin‐6 type cytokines and soluble interleukin‐6 receptor in patients with rheumatoid arthritis Tadeusz Robak, A Gladalska, Henryk Stepien et al. · Mediators of Inflammation Open access 1998 164
30 Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab John Francis Seymour et al. · Blood Open access 23 May 2022 158
31 CAR-NK Cells in the Treatment of Solid Tumors Ewa Wrona, Maciej Borowiec, Piotr Potemski · International Journal of Molecular Sciences Open access 31 May 2021 155
32 Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity Tadeusz Robak, Ewa Lech‐Marańda, Anna Korycka et al. · Current Medicinal Chemistry Nov 2006 153
33 Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial Carsten Utoft Niemann et al. · The Lancet Oncology Open access 6 Nov 2023 149
34 Current and emerging therapies for acute myeloid leukemia Tadeusz Robak, Agnieszka Wierzbowska · Clinical Therapeutics 2009 148
35 A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older Jean‐Luc Harousseau et al. · Blood Open access 21 May 2009 147
36 Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study Tadeusz Robak et al. · The Lancet Oncology Open access143 authors 19 Oct 2018 144
37 A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma Robert Z. Orlowski, Liana Gercheva, Cathy D. Williams et al. · American Journal of Hematology Open access 8 Oct 2014 135
38 Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma Wojciech J. Jurczak, Pier Luigi Zinzani, Gianluca Gaïdano et al. · Annals of Oncology Open access 9 Feb 2018 132
39 A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer C. Manegold, Nico van Zandwijk, A. Szczęsna et al. · Annals of Oncology Open access 5 Apr 2011 127
40 Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer Karolina Przybyłowska, Anita Kluczna, Marek Zadrożny et al. · Breast Cancer Research and Treatment 2 Nov 2005 126
41 Safety and Tolerability of Antibody-Drug Conjugates in Cancer Anna Wolska, Tadeusz Robak · Drug Safety Open access 16 Jan 2019 123
42 Evaluation of the effectiveness of the prepectoral breast reconstruction with Braxon dermal matrix: First multicenter European report on 100 cases Raghavan Vidya, Jaume Masià, Simon Cawthorn et al. · The Breast Journal Open access 8 May 2017 119
43 Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma Michael Wang et al. · Leukemia Open access 26 Sep 2019 115
44 Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque et al. · Blood Advances Open access 4 Sep 2020 112
45 Protective action of melatonin against oxidative DNA damage—Chemical inactivation versus base-excision repair Tomasz Śliwiński, Wioletta Rozej, Alina Morawiec-Bajda et al. · Mutation Research/Genetic Toxicology and Environmental Mutagenesis 10 Aug 2007 111
46 Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer Janusz Błasiak, Michał Arabski, Renata Krupa et al. · Mutation research. Fundamental and molecular mechanisms of mutagenesis 29 May 2004 110
47 The risk of atherosclerosis in patients with chronic kidney disease Sylwia Olechnowicz-Tietz, Anna Gluba-Brzózka, Anna Maria Paradowska et al. · International Urology and Nephrology Open access 12 Mar 2013 105
48 Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer Piotr Potemski, Renata Kusińska, Cezary W. Watała et al. · Oncology 2005 104
49 Hairy-cell leukemia variant: Recent view on diagnosis, biology and treatment Tadeusz Robak · Cancer Treatment Reviews 17 Jun 2010 102
50 Lipid peroxidation and glutathione peroxidase activity relationship in breast cancer depends on functional polymorphism of GPX1 Ewa Jabłońska, Jolanta Gromadzińska, Beata Pepłońska et al. · BMC Cancer Open access 7 Oct 2015 102

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.